VACH — Voyager Acquisition Corp./Cayman Islands
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2006815 ·
Last close
$17.11
Market Cap
$433.00M
52W High
$18.16
52W Low
$8.40
ADV30
10,506
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,192,818 | 180,498 | 272,279,955 | 32,790 | 286,728,104 |
| Dec 2025 | 0 | — | -873,510 | 1,705,388 | 270,056,383 | 182,103 | 13,339,118 |
| Sep 2025 | 0 | — | -405,805 | 2,358,611 | 267,548,197 | 252,350 | 12,536,321 |
| Jun 2025 | 0 | — | -240,935 | 2,491,996 | 264,824,119 | 92,494 | 12,170,854 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,730,468
Investing CF
$0
Financing CF
$255,611,753
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.24
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-15,338,498
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-3,713,068
Pretax Income TTM
$6,736,493
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,785,259 | 8,989,141 | 270,056,383 | 13,339,118 | — | -486,182 |
| Dec 2024 | 0 | -702,959 | 4,141,371 | 259,812,091 | 12,083,967 | — | -703,468 |
| Dec 2023 | — | — | — | 71,680 | 76,680 | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNA | Ginkgo Bioworks Holdings, Inc. | $439.16M | $8.23 | — |
| CCCC | C4 Therapeutics, Inc. | $422.37M | $3.82 | — |
| ARTV | Artiva Biotherapeutics, Inc. | $446.04M | $9.18 | — |
| IPSC | Century Therapeutics, Inc. | $414.82M | $2.30 | — |
| OCGN | Ocugen, Inc. | $413.00M | $1.22 | — |
News headlines (Yahoo Finance, 1h cache)
VERAXA Biotech (VRXA) Completes Business Combination, Begins Trading on Nasdaq
2026-06-11 19:30 · Yahoo
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
2026-06-10 20:15 · Yahoo
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC
2026-05-28 16:53 · Yahoo
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
2026-05-28 05:11 · Yahoo
Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG
2026-03-13 10:00 · Yahoo
Voyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AG
2026-03-11 10:00 · Yahoo
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
2026-03-02 06:00 · Yahoo
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
2025-07-17 12:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.